Arrowhead Research | ARWR - Los Gastos Financieros De La Deuda





Los Gastos Financieros De La Deuda Cambio Fecha
Agios Pharmaceuticals USD 1.39B 85.53M 2025-09
Alnylam Pharmaceuticals USD 129.34M 84.94M 2025-12
Anika Therapeutics 189.44M 1.76M 2025-09
Arrowhead Research USD 22.5M 811K 2025-12
Heron Therapeutics USD 600K 100K 2024-12
Incyte USD 582K 10K 2025-12
Ionis Pharmaceuticals USD 18M 0 2025-12
Ligand Pharmaceuticals USD 910K 243K 2025-09
Merck USD 412M 85M 2025-12
Moderna USD 12.14B 12.13B 2025-09
Nektar Therapeutics USD 6.02M 420K 2024-09
Novartis USD 304M 23M 2025-12
Sarepta Therapeutics USD 7.56M 2.33M 2025-09
TG Therapeutics USD 6.53M 187K 2025-12
Ultragenyx Pharmaceutical USD 19M 4.85M 2025-12
Vertex Pharmaceuticals USD 3.3M 0 2025-12
Xencor USD 7.35M 311K 2025-12